Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood-stem-cell transplantation. N Engl J Med 2000;343: 750-8.
McSweeney PA, Niederwieser D, Shizuru J, Sandmaier BM, Molina A, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-400.
Baron F, Baudoux E, Frere P, Tourqui S, Schaaf-Lafontaine N, Greimers R, et al. Nonmyeloablative stem cell transplantation with CD8-depleted or CD34- selected peripheral blood stem cells. J Hematother Stem Cell Res 2002; 11:301-14.
Baron F, Fillet G, Beguin Y. Erythropoiesis after nonmyeloablative stem-cell transplantation is not impaired by inadequate erythropoietin production as observed after conventional allogeneic transplantation. Transplantation 2002;74:1692-6.
Baron F, Siquet J, Schaaf-Lafontaine N, Baudoux E, Hermanne JP, Fillet G et al. Pre-emptive immunotherapy with CD8-depleted donor lymphocytes after CD34-selected allogeneic peripheral blood stem cell transplantation. Haematologica 2002;87:78-88.
Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 tandem meetings. Biol Blood Marrow Transplant 2001;7:473-85.
Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988;6:1562-8.
Baron F, Beguin Y. Nonmyeloablative allogeneic hematopoietic stem cell transplantation. J Hematother Stem Cell Res 2002;11:243-63.
Bregni M. Foreword. Haematologica 2002;87(8 Suppl):1.
Igarashi T, Mena O, Re F, Srinivasam R, Childs R. Exploring the role of allogeneic immunotherapy for non-hematologic malignancies: proof of concept and potential immune mechanisms of graft-vs-tumor effects in solid tumors. Haematologica 2002;87(8 Suppl):2-5.
Chung CY, Ueno NT. Non-myeloablative allogeneic peripheral blood progenitor cell transplantation for metastatic breast cancer and metastatic renal cell carcinoma: the M.D. Anderson Cancer Center experience. Haematologica 2002;87(8 Suppl):6-9.
Carella AM, Corsetti MT, Beltrami G, Carella M Jr, Scalzulli P, Aieta M, et al. Autografting and non-myeloablative allogeneic stem cell transplantation in metastatic breast cancer. Haematologica 2002;87(8 Suppl):10-1.
Peccatori J, Ciceri F, Bernardi M, Corti C, Pescarollo A, Servida P, et al. Evidence of allogeneic graft-versus-tumor effect in prostate and ovarian cancer. Haematologica 2002;87(8 Suppl):12-4.
Blaise D, Faucher C, Bay JO, Michallet M, Boiron JM, Cahn JY, et al. Allogeneic immunotherapy in patients suffering from advanced solid tumors. Haematologica 2002;87(8 Suppl):15-6.
Siena S, Pedrazzoli P, Giorgiani G, Renga M, Locatelli F. Allogeneic hematopoietic stem cell transplantation for solid tumors other than renal cell cancer. Haematologica 2002;87(8 Suppl):17-20.
Dazzi F, Macchiarulo E, Marktel S, Simpson E. Mechanisms of graft-versus-malignancy in humans. Haematologica 2002;87(8 Suppl):21-4.
Barkholt L, Hentschke P, Uzunel M, Mattsson J, Wersall P, Pisa P, et al. Non-myeloablative hematopoietic stem cell transplantation for metastatic solid tumors. Haematologica 2002;87(8 Suppl):25-9.
Slavin S, Morecki S, Shapira M, Or R. Non-myeloablative stem cell transplantation and targeted immunotherapy for the treatment of metastatic solid tumors. Haematologica 2002;87(8 Suppl):30-3.